Royalty Pharma plc

RPRX

GB00BMVP7Y09

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-20 EDT			5-day change	1st Jan Change
27.48 ^USD	+0.77%		-3.17%	-2.17%

05-16	Transcript : Royalty Pharma plc Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
05-14	Transcript : Royalty Pharma plc Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM

Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2024

May 09, 2024 at 07:00 am

Royalty Pharma plc reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 568 million compared to USD 684 million a year ago. Net income was USD 5 million compared to USD 341 million a year ago.

Latest news about Royalty Pharma plc

Transcript : Royalty Pharma plc Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	05-15
Transcript : Royalty Pharma plc Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM	05-14
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading	05-09	MT
Royalty Pharma to Acquire Frexalimab Royalties, Milestones for $525 Million in Cash	05-09	MT
Royalty Pharma's Q1 Net Income, Revenue Falls	05-09	MT
Transcript : Royalty Pharma plc, Q1 2024 Earnings Call, May 09, 2024	05-09
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q1 Revenue $568M, vs. Street Est of $709.5M	05-09	MT
Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug	05-03	MT
Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	04-17	MT
Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	04-17	CI
Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	04-09	MT
Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM	03-05
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	02-20	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating	02-20	MT
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023.	02-15	CI
Royalty Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
Royalty Pharma Swings to Q4 Net Income, Revenue Increases	02-15	MT
Transcript : Royalty Pharma plc, Q4 2023 Earnings Call, Feb 15, 2024	02-15
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15	CI
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q4 Revenue $596M, vs. Street Est of $674.5M	02-15	MT
Novartis wants to swallow Morphosys - access to beacon of hope	02-06	DP
Royalty Pharma Raises Quarterly Dividend by 5% to $0.21 per Class A Share, Payable March 15 to Shareholders of Record on Feb. 16	01-19	MT
Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024	01-19	CI
Transcript : Royalty Pharma plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM	01-09

Chart Royalty Pharma plc

Duration

Period

More charts

Company Profile

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertexâs Trikafta, GSKâs Trelegy, Rocheâs Evrysdi, Johnson & Johnsonâs Tremfya, Biogenâs Tysabri and Spinraza, AbbVie and Johnson & Johnsonâs Imbruvica, Astellas and Pfizerâs Xtandi, Novartisâ Promacta, Pfizerâs Nurtec ODT and Gileadâs Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Sector

Pharmaceuticals

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Royalty Pharma plc

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.27 USD

Average target price

45.75 USD

Spread / Average Target

+67.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROYALTY PHARMA PLC	-2.17%	12.3B
ELI LILLY AND COMPANY	+34.35%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-3.49%	372B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	294B
ASTRAZENECA PLC	+14.11%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+9.21%	168B

Other Pharmaceuticals